Hepatitis C Therapeutics in Asia-Pacific Markets Will Be Valued At $8.31 Billion By 2023 - Transform the Clinical and Commercial Landscape

ResearchMoz added Latest Research Report titled " Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape " to it's Large Report database.

Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape

Summary

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV), which can lead to acute and chronic hepatitis infection. According to the World Health Organization (WHO), in 2015 there were 1.75 million new HCV infections globally, and approximately 399,000 people die each year from hepatitis C, mostly due to cirrhosis and hepatocellular carcinoma. The APAC region has diverse HCV epidemiology, with prevalence ranging from 0.1% to 4.7%, and a unique genotype (GT) distribution. Acute HCV infection is usually asymptomatic, and 15-45% of people spontaneously clear the virus within six months of infection without any treatment, while the remaining 55-85% develop chronic HCV infection.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1313842

The hepatitis C market is currently dominated by high-performance regimens comprising new-generation DAAs. The treatment algorithms have shifted away rapidly from interferon-based therapies, and towards interferon-free DAA combination therapies that can cure most patients in as little as eight to 12 weeks, without ribavirin. In the highly competitive hepatitis C treatment landscape, where new combination therapies match each other closely in terms of safety and efficacy, one key differential is patient segment coverage. A number of factors that have conventionally been used to predict treatment outcome, including HCV genotypes, previous treatment history, and a patients liver and kidney conditions, are also used to define target patient populations for new therapies.

The late-stage hepatitis C pipeline is predominantly composed of DAA regimens targeting HCV NS5A, NS5B polymerase, and NS3/4A protease. The most advanced of the promising pipeline agents are Gileads sofosbuvir/velpatasvir/voxilaprevir and AbbVies glecaprevir/pibrentasvir, which have been studied in Phase III clinical trials. Due to the highly effective late-stage pipeline drugs and marketed products, developers of HCV NS5A, NS5B polymerase and NS3/4A protease in earlier stages of clinical development are not aiming to dominate the market, but rather to earn a place as a me too product.

Browse more details @ http://www.researchmoz.us/hepatitis-c-therapeutics-in-asia-pacific-markets-to-2023-presence-of-outstanding-direct-acting-antivirals-and-late-stage-pipeline-to-transform-the-clinical-and-commercial-landscape-report.html

Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 12
2.4 HCV Life Cycle 13
2.4.1 NS3/NS4A Protease 13
2.4.2 NS5A 13
2.4.3 NS5B Polymerase 13
2.5 Etiology and Pathophysiology 13
2.5.1 Pathophysiology 14
2.6 Diagnosis 18
2.7 Disease Progression 18
2.7.1 Acute Stage 18
2.7.2 Chronic Stage 19
2.7.3 End Stage 19
2.7.4 Factors Affecting Progression 19
2.7.5 Co-morbidities and Complications 20
2.8 Prognosis 20
2.9 Treatment Options and Treatment Algorithm 21
2.9.1 Treatment Options 21
2.9.2 Treatment Algorithm 25
2.9.3 Non-pharmacological Treatments 27
3 Marketed Products 29
3.1 Overview 29
3.2 Single Component Direct-Acting Antivirals 30
3.2.1 Sovaldi (Sofosbuvir) - Gilead Sciences 30
3.2.2 Daklinza (Daclatasvir) - Bristol-Myers Squibb 31

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Hepatitis C Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, Forecast And Opportunities 2014 - 2020

ResearchMoz added Latest Research Report titled " Hepatitis C Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020 " to it's Large Report database.

Hepatitis is defined as the inflammation of the liver due to an infection by a virus or other causative organism or toxin. Hepatitis C on the other hand, is primarily as a result of the infection by hepatitis C virus (HCV). With a cure rate between 50%-80%, and no commercially available vaccine as of yet, hepatitis C is considered a deadly disease with a moderate to high infection rate. It is the leading cause for liver transplantation in the U.K and North America.

The transmission of this virus in a majority occurs from injectables drug abuse, as the virus can only be transmitted via blood-to-blood contact. The secondary transmission factors include tattooing, sexual contact, healthcare (blood transfusion, organ transplant) mishaps, and other rare unknown cases. HIV infected individuals and AIDS patients too are at a higher risk of infection. The diagnosis of Hepatitis C is also very tricky as there lays a risk of misdiagnosis as the virus can go undetected in a liver biopsy sample. Liver enzyme levels may remain normal for an infected person for years, in some cases an infected person may go as long as 30 years without showing any symptoms of infection.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=213284

PCR amplification of purified and centrifuged biopsy samples done at specified time intervals are the best proven method for near accurate diagnosis.

This process is done so as to remove any errors caused as a result of false negatives by antibody immunoassay testing. However since PCR testing is quite expensive, initial screening is usually done via immunoassay method, in addition, immunoassay also determines the viral load and thereby help identify the stage of infection between acute and chronic. The acute stage of disease can generally be cured in majority of the cases, in some cases spontaneous curing has also been observed. Complete cure rate cannot be a possibility as Hepatitis C virus has various strains and is found to be mutative in nature. Chronic cases are seen in a majority of infected individuals and are also curable in some cases, but again among the majority, liver cirrhosis is observed, which may then require liver transplantation. Transplantation requires to be done with continuous medication, as chances of reinfection are very high. Therapy for Hepatitis C is not definitive but is generally done with a combination of medicines, namely pegylated-interferon-alpha and ribavirin, which is an antiviral. Other medications include boceprevir, ledipasvir, telaprevir, sofosbuvir and the novel simeprevir and sovaldi. These are either given as an addition to ribavirin or as a replacement, depending upon the condition, contraindication, genotype of virus and patient history.

Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

At present the cost of the antiviral and interferon market remains the biggest hurdle for the proliferation of Hepatitis C therapeutics market. The prices vary from few hundred dollars to hundreds of thousands of dollars for a single dose. Insurances companies generally do not cover the complete cost of drugs in standard covers, often individuals who have very high premium are the only ones able to afford the treatment. The ongoing research into vaccination may also provide as a restraint in the future, as preventive vaccination has always shown greater success versus therapeutics.

The market for Hepatitis C therapeutics remains in billions, with new combinations being patented every year, and each having their own market segment. They are at present one of the most sought after investment segment in the healthcare drugs industry. With entry of Asian players the prices too are bound to decrease, thereby potentially increasing therapeutics market. The North American market is the highest market by volume, followed by Europe, as in these regions reported cases are high in number, and so is the affordability of drugs.

The major cause for Hepatitis C transmission in developed nations is intravenous narcotic/psychedelic drug abuse, which is common in these regions. In developing markets of Asia and South America, the leading cause for transmission is healthcare exposure and their poor standards. This along with their population size make for a large market, however unavailability of affordable drugs is often the reason why markets haven’t been proliferated as of yet. However the recent growth of market in Asia Pacific is a positive sign for potential manufacturers. The rest of the world also follows a similar pattern.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

    North America
    Asia Pacific
    Europe
    Rest of the World

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG